文献速递慢阻肺

生长分化因子-15可预测慢阻肺患者重要疾病结局

Growth differentiation factor-15 is a predictor of important disease outcomes in patients with COPD.
PubMed 文献 · Eur Respir J · 2017-03-15

研究纳入413例来自Bergen慢阻肺队列的COPD患者,基线FEV1<80%预计值且FEV1/FVC<0.7,均有吸烟史。随访3年观察急性加重与肺功能变化,随访9年观察死亡。高GDF15水平与更高的年急性加重率、更高死亡率和FEV1及FVC下降更快独立相关。

要点

  • 高GDF15水平与COPD患者年急性加重率升高独立相关。
  • 高GDF15水平与COPD患者死亡率升高独立相关。
  • 高GDF15水平与FEV1和FVC下降更快相关。

核心结论

  • 在COPD患者中,高GDF15水平与更高的年急性加重率、更高死亡率和FEV1及FVC下降更快独立相关。

研究设计与样本

  • 研究纳入Bergen COPD Cohort Study中413例COPD患者,基线FEV1<80%预计值、FEV1/FVC<0.7且有吸烟史。
  • 基线测量肺功能、去脂体重指数、血气及血浆GDF15,随访3年观察急性加重与肺功能变化,随访9年观察死亡。

主要发现

  • 血浆GDF15中位数为0.86 ng·mL-1(四分位距0.64-1.12 ng·mL-1),分布非正态,按分类变量分析。
  • 高GDF15水平与更高急性加重率相关,调整后发生率比1.39(95% CI 1.1-1.74,p=0.006)。
  • 高GDF15水平与更高死亡率相关,风险比2.07(95% CI 1.4-3.1,p<0.001)。
  • 与低GDF15水平相比,高GDF15水平者FEV1下降4.29% versus 3.25%、FVC下降2.63% versus 1.44%(两者p<0.01)。

临床怎么用

  • GDF15可作为COPD患者急性加重、死亡及肺功能下降风险的预测指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Increased levels of growth differentiation factor-15 (GDF15) are associated with cachexia, cardiovascular disease and all-cause mortality. The role of GDF15 in chronic obstructive pulmonary disease (COPD) is unknown.The study included 413 patients with COPD from the Bergen COPD Cohort Study. All patients had a forced expiratory volume in 1 s (FEV1) <80% predicted, a FEV1 to forced vital capacity (FVC) ratio <0.7 and a history of smoking. Spirometry, fat free mass index, blood gases and plasma GDF15 were measured at baseline. Patients were followed for 3 years regarding exacerbations and changes in lung function, and 9 years for mortality. Yearly exacerbation rate, survival and yearly change in FEV1/FVC were evaluated with regression models.Median plasma GDF15 was 0.86 ng·mL-1 (interquartile range 0.64-1.12 ng·mL-1). The distribution was not normal and GDF15 was analysed as a categorical variable. High levels of GDF15 were associated with a higher exacerbation rate (incidence rate ratio 1.39, 95% CI 1.1-1.74, p=0.006, adjusted values). Furthermore, high levels of GDF15 were associated with higher mortality (hazard ratio 2.07, 95% CI 1.4-3.1, p<0.001) and an increased decline in both FEV1 (4.29% versus 3.25%) and FVC (2.63% versus 1.44%) in comparison to low levels (p<0.01 for both).In patients with COPD, high levels of GDF15 were independently associated with a higher yearly rate of exacerbations, higher mortality and increased decline in both FEV1 and FVC.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Husebø GR, Grønseth R, Lerner L, et al. Growth differentiation factor-15 is a predictor of important disease outcomes in patients with COPD. Eur Respir J. 2017. PMID: 28298399. doi:10.1183/13993003.01298-2016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。